title: Infectious keratitis after LASIK.
abstract: OBJECTIVE
  To report the clinical course, management, and outcomes of culture-proven infectious keratitis in 15 eyes of 13 subjects after LASIK.
  
  
  METHODS
  Retrospective, noncomparative, interventional case series.
  
  
  METHODS
  Fifteen eyes of 13 subjects who underwent LASIK and developed culture-positive keratitis.
  
  
  METHODS
  Infectious keratitis was encountered in the operative eyes between 1 day and 450 days. Cultures were obtained, and topical antibiotic therapy was administered in all cases. Some cases required flap lifting, irrigation, and soaking of the bed with antibiotics, flap amputation, or further surgical intervention.
  
  
  METHODS
  Time periods from onset to diagnosis, from clinical diagnosis to clinical resolution, final acuities, microbiologic profiles, and medical and surgical interventions were reviewed.
  
  
  RESULTS
  Onset of symptoms of infection varied, depending on the infectious organism. Bacterial organisms tended to present earlier, whereas mycobacterial and fungal organisms had a later mean onset of presentation. Furthermore, the atypical organisms such as mycobacteria, fungus, and acanthamoeba also had a more delayed diagnosis, resulting in a prolonged disease course.
  
  
  CONCLUSIONS
  Infectious keratitis after LASIK is a potentially vision-threatening complication. Onset of symptoms varies depending on causative agents. Furthermore, atypical organisms in the interface or beneath the flap can pose both diagnostic and therapeutic dilemmas. Location in the interface can make it more difficult to culture the organisms and prevent adequate penetration of topical antibiotics.
authors.affiliation: Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida.
authors.forename: Carol L
authors.initials: CL
authors.lastname: Karp
authors.forename: Sonal S
authors.initials: SS
authors.lastname: Tuli
authors.forename: Sonia H
authors.initials: SH
authors.lastname: Yoo
authors.forename: David T
authors.initials: DT
authors.lastname: Vroman
authors.forename: Eduardo C
authors.initials: EC
authors.lastname: Alfonso
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Huang
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Pflugfelder
authors.forename: William W
authors.initials: WW
authors.lastname: Culbertson
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents; D001419:Bacteria / Q000302:isolation & purification; D003315:Cornea / Q000382:microbiology*; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D015818:Eye Infections, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D006801:Humans; D007634:Keratitis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D020731:Keratomileusis, Laser In Situ / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000601:surgery*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents